Triplet (FOLFOXIRI) Versus Doublet (FOLFOX or FOLFIRI) Regimen as First Line Treatment in Metastatic Colorectal Carcinoma, a Prospective Phase II, Randomized Controlled Trial
Open Access
- 1 October 2022
- journal article
- research article
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 23 (10) , 3421-3429
Abstract
Background: The outcomes of treatment of metastatic colorectal cancer (mCRC) is still unsatisfactory. Several trials approved that, the upfront treatment with triplet regimen included fluorouracil, leucovorin, irinotecan and oxaliplatin improved the outcomes of patients with metastatic disease as compared to standard doublet regimen. The objective of our study is evaluating the impact of upfront treatment with triplet (FOLFOXIRI) regimen on both oncological outcomes (response rate and survival) and patients’ tolerability in comparison to the standard doublet regimen. Methods: We randomly enrolled 64 patients with a newly diagnosed unresectable mCRC to receive either FOLFOXIRI (experimental arm) or FOLFIRI or FOLFOX4 (control arm) biweekly up to 12 cycles. The primary endpoints are overall response rate (RR) and patients’ tolerability. The secondary endpoints are the progression free and overall survival. Result: There was a significantly increase in RR (59% vs 37%) and complete remission rate (CR) (6.3% and 3.1%, respectively (P = 0.045) for the triplet therapy group compared to control group. Consequently, an increased rate of secondary resection of metastasis (21.9% vs 3.1% respectively; P=0.023). The FOLFOXIRI regimen was associated with higher rate of grade 3/4 toxicity but not statistically significant except febrile neutropenia (6.2%; P=0.03). There was numerical prolongation in the median PFS in the FOLFOXIRI group on compared to control group but not significantly (9 versus 8 months; P=0.11). The median OS was 20 and 22 months in FOLFOXIRI arm and control arm respectively with no statistically significant difference (P=0.57). Conclusion: FOLFOXIRI had a higher efficacy and higher conversion rate to secondary resection over the doublet regimen as an upfront treatment option, coupled with a manageable adverse event, but failed to improve the survival outcomes.Keywords
This publication has 15 references indexed in Scilit:
- A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal CancerTargeted Oncology, 2015
- First-line chemotherapy for mCRC—a review and evidence-based algorithmNature Reviews Clinical Oncology, 2015
- Strategies of Sequential Therapies in Unresectable Metastatic Colorectal Cancer: A Meta-AnalysisCurrent Oncology, 2014
- A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?British Journal of Cancer, 2014
- FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancerEuropean Journal of Cancer, 2014
- A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases. The METHEP TrialAnnals of Surgical Oncology, 2013
- The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International ConsensusThe Oncologist, 2012
- Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastasesBritish Journal of Cancer, 2010
- Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord OvestJournal of Clinical Oncology, 2007
- Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia MeridionaleJournal of Clinical Oncology, 2005